Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel in pediatric recurrent/refractory solid tumors
NCT01962103Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2013
- Primary completion
- Dec 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of nab-paclitaxel in solid tumor, neuroblastoma, rhabdomyosarcoma (RMS) and 1 more (9 arms), sponsored by Celgene Corporation. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Number of Participants With Treatment-Emergent Adverse Events and 1 more. Started Dec 2013; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
solid tumorneuroblastomarhabdomyosarcoma (RMS)Ewing sarcoma
Beyond the preview
Go deeper on NCT01962103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962103.